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Introduction
Several hematologic complications such as anemia, 
thrombocytopenia, neutropenia, and coagulopathy caused by direct or 
indirect effects of HIV-1 have been reported in HIV-infected children 
[1]. HIV-1 can trigger acute and lethal atypical episodes of the Hemolytic 
Uremic Syndrome (HUS) [2,3], and Thrombotic Thrombocytopenic 
Purpura (TTP) [4-8]. The main histological feature of HIV-associated 
HUS or TTP is microvascular thrombosis with endothelial damage, 
affecting predominately the kidney and brain, and potentially other 
tissues as well [2-9].
Classic TTP results from the deficiency or malfunction of a 
desintegrin and metalloproteinase with a thrombospondin type 1 
motif, member 13 (ADAMTS13), which fails to cleave the ultralarge 
multimers of the von-Willebrand factor (v-WF) that are released by 
endothelial cells [10]. In contrast, HUS and other HIV-hematological 
complications that mimic the clinical features of TTP, including 
Immune Thrombocytopenic Purpura (ITP), are triggered by different 
immunological or infectious mechanisms [3-8]. Importantly, effective 
antiretroviral treatments decrease all HIV-associated hematologic co-
morbidities, including HUS, TTP, and ITP underlying a unique role of 
the virus and the cytokines released by infected cells in the pathogenesis 
of these diseases [11,12]. Despite the overall progress made in the 
treatment of HIV-infection, HIV- infected children continue to be at 
high risk of developing severe cases of HUS and TTP, particularly in 
populations for whom treatment is not available or adherence is poor 
[2-7]. Nonetheless, very little information is available to guide the 
treatment of these children. Here, we describe a case of TTP in a 16 
year old female with perinatally acquired HIV-infection who presented 
with severe thrombocytopenia, microangiopathic hemolytic anemia 
(MAHA), and a past medical history of HIV-associated ITP (HIV-ITP), 
and later developed an acute hemorrhagic stroke. This patient showed 
a remarkable clinical response to the re-initiation of the antiretroviral 
therapy (ART) in combination with plasma exchange therapy, and was 
able to achieve a complete recovery without developing significant 
chronic renal or neurological sequelae.
Case Presentation
A 16-year old African American HIV-infected female presented to 
the emergency department (ED) with three days history of continuous 
oral bleeding after biting her lip. She also reported gingival bleeding 
after brushing her teeth and two small bruises on her forearm and 
thigh in the preceding 3 weeks. She denied any joint pain or swelling, 
fever, diarrhea, melena, or hemoptysis. The patient was prescribed 
ART with zidovudine (AZT) and lamivudine (3TC) (as (Combivir®), 
plus tenofovir disoproxil fumarate (TDF) and lopinavir (Kaletra®). On 
presentation to the ED, she reported significant non-adherence to ART. 
The patient past medical history revealed a previous episode of anemia 
and symptomatic (petechiae) thrombocytopenia (10×109/L) at the age 
of 13 years treated with steroids. During this episode, after extensive 
evaluation including bone marrow aspiration, she was diagnosed 
with perinatally acquired HIV-1 infection, Center for Disease Control 
(CDC) category B3. Her mother was diagnosed with HIV-1 infection 
a few years before. Past medical history also included febrile seizures, 
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recurrent otitis media, bacterial endocarditis, and pneumonia. At the 
time of HIV diagnosis her CD4+ cell count was 160 cells/mm3 (11%) 
and the HIV RNA viral load (VL) was 36,700 copies/ mL with no 
resistance-associated mutations on HIV-1 phenotype. The initial ART 
included stavudine (d4T), lamuvidine (3TC) and lopinavir/ritonavir 
(Kaletra®). With intermittent adherence to the ART, her CD4+ cell 
count remained fluctuant in the range of 12-30%, and her HIV-1 RNA 
VL ranged between 1,049 to 99,765 copies/mL. Eighteen months after 
initiation of ART the patient had a repeat episode of asymptomatic 
thrombocytopenia (33×109/L) treated with a single dose of RhoD 
immune globulin (Ig) (WinRho®, Cangene Corporation; Winnepeg, 
Canada). Except for this single episode, her platelets remained in the 
range of 148-262×109/L. Four months prior to her presentation to 
the ED, the hemoglobin (Hb) and hematocrit (Hct) were 11.5 g/dL 
and 34.9% respectively, with a platelet count of 178×109/L. Due to the 
development of 184V HIV mutation six months prior to her visit to the 
ED, the ART was changed as described above. On initial presentation to 
the ED, the patient was afebrile, tachycardic (90 beats/min), tachypneic 
(28 respirations/min) with a mildly elevated blood pressure (132/76 
mm Hg). Physical examination was notable for a bite wound on the 
lower lip that was oozing blood. Small petechiae (4 mm) were noted on 
the forearms and a slightly larger purpura (50 mm) on the thighs. Aside 
from bilateral cervical lymphadenopathy, the remainder of the physical 
exam was normal. Laboratory studies revealed severe normocytic 
anemia and thrombocytopenia, elevated aspartate aminotransferase 
(AST), elevated lactate dehydrogenase (LDH) and total bilirubin, with 
a normal coagulation profile (Table 1). Peripheral smear displayed 
schistocytes, polychromasia, anisocytosis, and poikilocytosis. A 
urinalysis demonstrated proteinuria and hemoglobinuria; a pregnancy 
test was negative. 
The patient received a transfusion with packed red blood cells 
(PRBC) and given the history of the HIV-associated ITP responding to 
Rho D Ig, was started on daily infusions of intravenous immunoglobulin 
G (IVIg) for initial diagnosis of immune thrombocytopenic purpura 
(ITP) associated with HIV-1 infection. This treatment lead to an increase 
in platelets count to 12×109/L within 24 hours. Platelet transfusion was 
reserved for signs of neurological deterioration and the prescribed ART 
was restarted. On hospital day (HD) #4, the patient acutely developed 
altered mental status with aphasia. An emergent head CT showed left 
hemispheric cerebral hemorrhages with mass effect and surrounding 
edema (Figure 1). The patient was transferred to the pediatric intensive 
care unit (PICU), where she experienced a generalized tonic-clonic 
seizure requiring intubation. At the time her Hb and Hct were 5.9 g/
dL and 17.2%, respectively with a platelet count of 18×109/L and an 
LDH of 2087 IU/L. Following an emergent transfusion of 4 random 
donor equivalent apheresis platelets (which led to platelet count of 
43×109/L within 24 hours) and PRBCs, (given initially through the 
COBE Spectra cell separator (Terumo BCT, Lakewood, CO), plasma 
exchange with fresh frozen plasma (FFP) replacement was initiated. 
A total of 7 plasma exchange procedures were performed with 1.3-1.9 
plasma volumes exchanged per procedure until near normalization of 
LDH and normal platelet count for two days. While undergoing plasma 
exchange, she was transfused twice with PRBCs, and was treated 
with methylprednisolone and levetiracetam. Two days after the PICU 
admission her neurological status improved and she was extubated. 
Though she initially demonstrated right facial and upper extremity 
weakness, these symptoms resolved by the time of discharge on HD #16 
and she displayed no residual neurologic damage, except for seizures 
well controlled with anticonvulsant therapy. A new ART regimen with 
AZT/3TC (Combivir®), TDF, and efavirenz (EFV) was started on HD 
#8. Interestingly, her HIV RNA VL decreased dramatically as a result 
of plasma exchange, and the decrease VL correlated with an increase 
in platelet count and a decrease in plasma LDH levels (Figure 2). A test 
for ADAMTS13 levels (performed at the Blood Center of Wisconsin 
prior to the start of plasma exchange) revealed an activity of < 5% 
(reference interval ≥ 67%), confirming the diagnosis of TTP despite no 
detectable inhibitory antibody (0.4 inhibitor units, reference interval ≤ 
0.4). The repeat test on HD # 10, after 7 plasma exchange procedures, 
Figure 1: Emergent head CT demonstrating the larger of two frontoparietal 
hemorrhages.
Test Patient Values Reference
Blood
Hemoglobin (Hb) 5.2 g / dL (10.8 – 13.3)
Hematocrit (Hct) 15.8 % (33.4-40.4)
Platelet count 3 K / uL (194-345)
Schistocytes 3+ None
Automated absolute reticulocytes 105.9 K / uL (41.6-65.1)
Automated reticulocyte count 5.32% (0.9-1.49)
Lactate dehydrogenase (LDH) 1173 IU / L (117-213)
Haptoglobin < 7 mg / dL (43-212)
Prothrombin time (PT) 13.4 sec (11.1-14.5)
Activated partial thromboplastin time
(aPTT) 32.7 sec (23.1-35.0)
International Normalized Ratio (INR) 1.06 (0.80-1.11)
Total bilirubin 1.5 mg / dL (< 0.8)
AST 101 U / L (0-26)
ALT 47 U / L (19-49)
Blood urea nitrogen 14 mg / dL (7-21)
Creatinine 0.4 mg / dL (0.5-1.1)
CD4+ count 299 cells (>350)
CD4+ % 12% (>25%)
HIV Viral Load 245,874 copies / mL (< 48)
Urine
Total protein 2+ None
Blood 3+ None
Urine RBC 1 per HPF (< 3)
Table 1: Initial Laboratory Findings.
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showed a significant increase in ADAMTS13 activity to 63%, and the 
inhibitory antibody test was not repeated. After discharge, the patient’s 
adherence to ART significantly improved, leading to undetectable 
HIV RNA levels (VL < 48 copies/mL) and a stable increase in CD4+ 
to 31% (563 cells/mm3) within 16 weeks. She suffered no permanent 
renal or neurologic deficits, except for seizure disorder well controlled 
with anticonvulsants, and maintained undetectable HIV-1 RNA VL 
and stable CD4+ cell counts 52 weeks after the start of the new ART 
regimen. Informed consent to report this case was obtained from the 
patient and her family and approved by the IRB at Children’s National 
Medical Center.
Discussion
This case illustrates the clinical dilemma generated by an adolescent 
female who presented with an acute episode of severe thrombocytopenia 
accompanied with MAHA and a past medical history of HIV-ITP. 
Because MAHA is not present in HIV-ITP [4], two different diseases 
were considered in the differential diagnosis. Initially, the patient did 
not present fever, neurological symptoms, or renal failure, therefore 
the diagnosis of HIV-ITP was prioritized, while in the mean time, 
additional tests were done to determine the etiology of the MAHA. In 
subsequent days, the patient developed neurological symptoms caused 
by a cerebral hemorrhage, and a decreased ADAMTS13 activity (<5 
%), confirmed the diagnosis of HIV-TTP. The patient had an excellent 
clinical response to plasma exchange therapy, in agreement with the 
outcome of previous adult cases of HIV-TTP [4,11,12]. These studies 
recommend the prompt initiation/re-initiation of ART in parallel 
with plasma exchange therapy to accelerate the remission of HIV-
TTP [4,11,12] and prevent lethal complications [13-16]. In summary, 
this case highlights the challenges and importance of making an early 
identification and treatment of children with HIV-TTP. 
Primary ITP, named recently “immune thrombocytopenia” 
to emphasize the immune mediated mechanism of the disease, is 
defined as isolated thrombocytopenia with normal bone marrow and 
absence of other causes of low platelets [17,18]. It involves acquired 
megakaryocytic thrombocytopenia with the shortened life of platelets 
due to immunological damage [17,18]. Secondary ITP, include all 
forms of immune thrombocytopenias that are due to an underlying 
disease, including HIV-1 infection [17]. The distinction between 
primary and secondary ITP forms is clinically relevant, because they 
have different natural history, pathogenesis, and treatment [18]. HIV-
ITP, is treated effectively with ART, short-term corticosteroids, IVIg 
and anti-D [17]. In our case, the patient received ART and IVIg, and 
the platelet count increased from 3×109/L to 18×109/L in a few days 
before plasma exchange therapy was initiated. This response may argue 
in favor of the diagnosis of ITP, however the rise in platelet count 
was inadequate to prevent the intracranial bleeding, and cannot be 
considered a successful response according to recent guidelines [17]. In 
contrast, the remarkable clinical response to plasma exchange therapy, 
strongly suggests that clinical symptoms were predominately caused by 
HIV-TTP. Interestingly, very few cases of HIV-associated TTP and ITP 
occurring in the same patients have been reported in the literature [19]. 
All these cases were adult patients, and the diagnosis of ITP preceded 
or followed the onset of TTP by years or months [19]. To the best of 
our knowledge, only one adult patient was described in whom both, 
ITP and TTP, were present simultaneously [19]. In this case, the platelet 
count did not improve during the plasma exchange treatment. Thus, 
although we cannot exclude the possibility that both diseases were 
present simultaneously in our patient, the dramatic response to plasma 
exchange therapy, and the clinical response of the only case reported in 
the literature [19], suggests that this possibility is unlikely.
Thrombotic microangiopahties (TMA) are characterized by the 
involvement of widespread occlusive microvascular thromboses 
resulting in thrombocytopenia, (MAHA), and variable symptoms 
of end-organ ischemia. Different primary or acquired etiologies 
contribute to the spectrum of TMA in HIV-infected patients, including 
disseminated intravascular coagulopathy (DIC). Children develop 
typical and atypical forms of HUS secondary to infectious pathogens 
(E. coli 0157:H7, Salmonella, Campylobacter, and Pneumococcus spp) 
[20-22], and underlying genetic defects such as deficiency in certain 
complement factors or proteins associated with processing the ultra-
large thrombogenic multimers of vWF [23-25]. In a previous study, we 
reported two fatal pediatric cases of atypical HIV-HUS of unknown 
etiology [3]. Thus, the pathogenesis of HIV-HUS is multifactorial, and 
it is not always possible to identify the primary factors triggering these 
events. The patient described in this report, had no history of recent 
gastrointestinal illness or family history consistent with any primary 
defect that could trigger HUS. DIC is sometimes included in the TMA 
spectrum, as its widespread thrombus formation can lead to MHA. 
On peripheral smear, DIC and TTP can be nearly indistinguishable, 
with both resulting in an overall thrombocytopenia. The hallmark 
consumptive coagulopathy with associated coagulation profile 
abnormalities, however, was missing in our patient [26,27]. Due to the 
combination of MAHA, thrombocytopenia, neurological symptoms, 
and decreased ADAMTS13 activity [24,25], our patient most closely fit 
the definition of TTP. The activity of ADAMTS13 increased from < 5% 
to 63% after 10 days of treatment with ART and seven plasma exchange 
procedures, in correlation with an excellent clinical recovery. Moreover, 
her underlying HIV diagnosis is consistent with reports of a unique role 
of HIV-1 in the pathogenesis of this disease.
Hereditary forms of TTP (e.g. Upshaw-Schulman syndrome) 
are due to a genetic deficiency of the metalloproteinase ADAMTS13 
[28]. The ADAMTS13 deficiency leads to the accumulation of high 
molecular weight vWF multimers, which in turn, form platelet rich 
clots that cause TMA lesions and microangiopathic hemolytic anemia. 
In acquired forms of TTP, reduced protease activity may be caused 
by the production of an autoimmune antibody against ADAMTS13; 
however, these autoantibodies cannot always be detected [29]. A recent 
summary presented at the 2012 American Society for Apheresis (ASFA) 
Consensus Conference on Classification, Diagnosis, Management, and 
Future Research in TTP showed that the autoantibody is present in 
































Figure 2: (A) Platelets (green line) and LDH (blue line) levels during hospital 
course; the light blue and light green areas indicate the reference interval for 
LDH and platelet count respectively, black bars indicate plasma exchange 
procedures; the pink bar indicates platelet transfusion; the black arrows and 
numbers demonstrate separate HIV-RNA viral loads in copies/mL; the asterisk 
(*S) identifies the stroke event.
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TTP reported in the literature however, show a significant decrease 
in the activity of ADAMTS13 [4,9,31,32]. The number of cases varies 
depending on the definition of HIV-TTP used in each study. Thus, 
we cannot be sure that all patients with HIV-HUS or other causes of 
MAHA were excluded from these studies. Alternatively, HIV-1 can play 
a unique role in the pathogenesis of HIV-TTP by causing widespread 
endothelial damage from direct viral or cytokine-mediated cell injury 
[4,9,32]. These changes cause the release of vWF triggering a localized 
coagulation cascade mainly in the renal and brain microvasculature, 
[4,31,32]. In our case, the patient’s decrease in ADAMTS13 activity 
was not associated with a detectable specific inhibitory antibody. 
However, considering that the ADMATS 13 activity only increased 
to 63% during recovery, we cannot exclude the presence of low 
inhibitor levels that were not detected with the test used. Repeat 
plasma exchange treatments led to the resolution of TTP through 
replenishing of the ADAMTS13 activity and reversing the platelet 
clot formation and platelet consumption (Figure 2). The rise in the 
platelet count in our patient was associated with a significant drop in 
HIV-1 RNA VL attributable to the re-initiation of ART and possibly, 
to the physical removal of viruses and circulating cytokines through 
the plasma exchange therapy. It is tempting to speculate that the 
removal of inflammatory cytokines and HIV virions through plasma 
exchange, could have reduced the endothelial damage and secondary 
release of vWF release [4,9,32]. Nonetheless, the more sustainable 
increase in platelet count was observed following the initiation of ART. 
This is consistent with other reports of HIV-associated TTP, where 
patients’ improvement was shown to be directly related to the virologic 
suppression [4-6,9,11,12,31,32]. The ability of ART to down-regulate 
inflammatory molecules on endothelial cells may play an additional 
role in this process [4,9,33-35]. In summary, all successful therapies 
of HIV-TMA lesions require the underlying treatment of the HIV-
infection [4,9,32].
Previous studies done before effective ART regimens were 
established, reported a poor prognosis for patients with HIV-TTP 
or TMA, with few patients surviving longer than 24 months [2-7]. 
Subsequent studies showed much better outcomes, suggesting that the 
prognosis may be more closely related to the stage of HIV-infection 
and severity of immunosuppression at the time of diagnosis, rather 
than the TTP event per se. More recent studies in adults indicate that 
approximately 80% of the HIV-infected patients with TTP can have 
a successful response to ART in combination with plasma exchange 
[4,7,12]. Moreover, it appears that patients with primary neurological 
symptoms characteristic of classic TTP, like in our case, are more 
responsive to plasma exchange [4].
Finally, it is worth mentioning that many AIDS-related disorders or 
viral infections associated with HIV-1 can cause symptoms similar to 
HIV-TTP. Furthermore, these patients may have ongoing renal and/or 
neurological symptoms, affecting the standard clinical criteria used to 
make an early diagnosis, or the decision when to initiate plasma exchange 
therapy. HIV associated anemia, neutropenia and/or thrombocytopenia 
are frequently seen at the time of the initial HIV-1 diagnosis and usually 
resolve with effective ART, unless they are associated with antiretroviral 
therapy. As discussed before, based on a past medical history of HIV-
ITP, the presence of severe thrombocytopenia in combination with 
other laboratory features of TMA may be overlooked. Another clinical 
dilemma in patients with HIV-TTP, is the decision to give platelet 
transfusions to patients with severe thrombocytopenia who need a 
catheter placement or other invasive procedures. Early complications 
of platelet transfusions given to patients with TTP resulted in the 
recommendation to avoid this treatment except for life-threatening 
bleeding [36]. However, a recent review of the Oklahoma TTP-HUS 
Registry, based on 382 consecutive patients, concluded that the evidence 
that platelet transfusions are harmful for patients with TTP is uncertain 
[30,37], in particular, if given simultaneously with the plasma exchange 
therapy [37,38]. Thus, all children with hematological complications 
of HIV and questionable adherence to ART need to be monitored 
closely as TMA lesions can develop in a relatively short period of time. 
Thrombocytopenia in the presence of schistocytes, elevated LDH and 
total bilirubin, decreased haptoglobin, and hemoglobinuria, are useful 
laboratory markers to identify a thrombotic process with microvascular 
destruction of erythrocytes. However all these changes are not always 
present or detected during the initial stages of TTP. In conclusion, the 
excellent recovery of this pediatric patient who suffered a hemorrhagic 
stroke, demonstrates the necessity of establishing a rapid diagnosis and 
treatment of HIV-TTP in children, and to sustain a long term reduction 
of the viral load in these patients.
Financial Support
National Institute of Health grants R01 HL 55605 and R01 102497 
R01 DK049419.
References
1. Abuzaitoun OR, Hanson IC (2000) Organ-specific manifestations of HIV 
disease in children. Pediatr Clin North Am 47: 109-125.
2. Boccia RV, Gelmann EP, Baker CC, Marti G, Longo DL (1984) A hemolytic-
uremic syndrome with the acquired immunodeficiency syndrome. Ann Intern 
Med 101: 716-717.
3. Turner ME, Kher K, Rakusan T, D'Angelo L, Kapur S, et al. (1997) A typical 
hemolytic uremic syndrome in human immunodeficiency virus-1-infected 
children. Pediatr Nephrol 11: 161-163.
4. Blazes DL, Decker CF (2004) Thrombotic Thrombocytopenic Purpura in HIV-
infected patients. Infect Dis Clin Pract 12: 99-106. 
5. Miller RF, Scully M, Cohen H, Roedling S, Starke R, et al. (2005) Thrombotic 
thrombocytopaenic purpura in HIV-infected patients. Int J STD AIDS 16: 538-
542.
6. Nosari AM, Landonio G, Caggese L, Cattaneo D, Muti G, et al. (1994) 
Thrombotic thrombocytopenic purpura associated with HIV infection: report of 
two cases. Haematologica 79: 280-282.
7. Hymes KB, Karpatkin S (1997) Human immunodeficiency virus infection and 
thrombotic microangiopathy. Semin Hematol 34: 117-125.
8. Rarick MU, Espina B, Mocharnuk R, Trilling Y, Levine AM (1992) Thrombotic 
thrombocytopenic purpura in patients with human immunodeficiency virus 
infection: a report of three cases and review of the literature. Am J Hematol 
40: 103-109.
9. Park YA, Hay SN, Brecher ME (2009) ADAMTS13 activity levels in patients 
with human immunodeficiency virus-associated thrombotic microangiopathy 
and profound CD4 deficiency. J Clin Apher 24: 32-36.
10. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, et al. (1998) von 
Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura 
and the hemolytic-uremic syndrome. N Engl J Med 339: 1578-1584.
11. Gruszecki AC, Wehrli G, Ragland BD, Reddy VV, Nabell L, et al. (2002) 
Management of a patient with HIV infection-induced anemia and 
thrombocytopenia who presented with thrombotic thrombocytopenic purpura. 
Am J Hematol 69: 228-231.
12. Hart D, Sayer R, Miller R, Edwards S, Kelly A, et al. (2011) Human 
immunodeficiency virus associated thrombotic thrombocytopenic purpura--
favourable outcome with plasma exchange and prompt initiation of highly active 
antiretroviral therapy. Br J Haematol 153: 515-519.
13. Copelovitch L, Kaplan BS (2008) The thrombotic microangiopathies. Pediatr 
Nephrol 23: 1761-1767.
14. Blanchette V, Bolton-Maggs P (2008) Childhood immune thrombocytopenic 
purpura: diagnosis and management. Pediatr Clin North Am 55: 393-420, ix.
Citation: Rakhmanina N, Wong ECC, Davis JC, Ray PE (2014) Hemorrhagic Stroke in an Adolescent Female with HIV-Associated Thrombotic 
Thrombocytopenic Purpura. J AIDS Clin Res 5: 311. doi:10.4172/2155-6113.1000311
Page 5 of 5
Volume 5 • Issue 6 • 1000311
J AIDS Clin Res
ISSN: 2155-6113 JAR an open access journal 
15. Geddis AE, Balduini CL (2007) Diagnosis of immune thrombocytopenic purpura 
in children. Curr Opin Hematol 14: 520-525.
16. Fogarty PF, Segal JB (2007) The epidemiology of immune thrombocytopenic 
purpura. Curr Opin Hematol 14: 515-519.
17. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, et al. (2011) The 
American Society of Hematology 2011 evidence-based practice guideline for 
immune thrombocytopenia. Blood 117: 4190-4207.
18. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, et al. (2009) 
Standardization of terminology, definitions and outcome criteria in immune 
thrombocytopenic purpura of adults and children: report from an international 
working group. Blood 113: 2386-2393.
19. Yospur LS, Sun NC, Figueroa P, Niihara Y (1996) Concurrent thrombotic 
thrombocytopenic purpura and immune thrombocytopenic purpura in an HIV-
positive patient: case report and review of the literature. Am J Hematol 51: 
73-78.
20. Elliott EJ, Robins-Browne RM (2005) Hemolytic uremic syndrome. Curr Probl 
Pediatr Adolesc Health Care 35: 310-330.
21. Banatvala N, Griffin PM, Greene KD, Barrett TJ, Bibb WF, et al. (2001) The 
United States National Prospective Hemolytic Uremic Syndrome Study: 
microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 183: 
1063-1070.
22. Ray PE, Liu XH (2001) Pathogenesis of Shiga toxin-induced hemolytic uremic 
syndrome. Pediatr Nephrol 16: 823-839.
23. Bonnardeaux A, Pichette V (2003) Complement dysregulation in haemolytic 
uraemic syndrome. Lancet 362: 1514-1515.
24. Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are 
all diseases of complement activation. Nat Rev Nephrol 8: 622-633.
25. Nabhan C, Kwaan HC (2003) Current concepts in the diagnosis and 
management of thrombotic thrombocytopenic purpura. Hematol Oncol Clin 
North Am 17: 177-199.
26. Levi M, Ten Cate H (1999) Disseminated intravascular coagulation. N Engl J 
Med 341: 586-592.
27. Kenet G, Strauss T, Kaplinsky C, Paret G (2008) Hemostasis and thrombosis in 
critically ill children. Semin Thromb Hemost 34: 451-458.
28. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, et al. (2001) Mutations 
in a member of the ADAMTS gene family cause thrombotic thrombocytopenic 
purpura. Nature 413: 488-494.
29. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease 
in acute thrombotic thrombocytopenic purpura. N Engl J Med 339: 1585-1594.
30. Sarode R, Bandarenko N, Brecher ME, Kiss JE, Marques MB, et al. (2013) 
Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis 
(ASFA) consensus conference on classification, diagnosis, management, and 
future research. J Clin Apher .
31. Gunther K, Garizio D, Nesara P (2007) ADAMTS13 activity and the presence 
of acquired inhibitors in human immunodeficiency virus-related thrombotic 
thrombocytopenic purpura. Transfusion 47: 1710-1716.
32. Brecher ME, Hay SN, Park YA (2008) Is it HIV TTP or HIV-associated thrombotic 
microangiopathy? J Clin Apher 23: 186-190.
33. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von 
Willebrand factor-cleaving protease in thrombotic microangiopathies: a study 
of 111 cases. Blood 98: 1765-1772.
34. Ray PE, Liu XH, Xu L, Rakusan T (1999) Basic fibroblast growth factor in HIV-
associated hemolytic uremic syndrome. Pediatr Nephrol 13: 586-593.
35. Ray PE, Soler-García AA, Xu L, Soderland C, Blumenthal R, et al. (2005) 
Fusion of HIV-1 envelope-expressing cells to human glomerular endothelial 
cells through an CXCR4-mediated mechanism. Pediatr Nephrol 20: 1401-1409.
36. Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in 
thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical 
experience in 108 patients. N Engl J Med 325: 398-403.
37. Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, et al. 
(2009) Clinical outcomes after platelet transfusions in patients with thrombotic 
thrombocytopenic purpura. Transfusion 49: 873-887.
38. Coppo P, Lassoued K, Mariette X, Gossot D, Oksenhendler E, et al. (2001) 
Effectiveness of platelet transfusions after plasma exchange in adult thrombotic 
thrombocytopenic purpura: a report of two cases. Am J Hematol 68: 198-201.
Submit your next manuscript and get advantages of OMICS 
Group submissions
Unique features:
• User friendly/feasible website-translation of your paper to 50 world’s leading languages
• Audio Version of published paper
• Digital articles to share and explore
Special features:
• 300 Open Access Journals
• 25,000 editorial team
• 21 days rapid review process
• Quality and quick editorial, review and publication processing
• Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
• Sharing Option: Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles
Submit your manuscript at: http://www.omicsonline.org/submission
Citation: Rakhmanina N, Wong ECC, Davis JC, Ray PE (2014) Hemorrhagic 
Stroke in an Adolescent Female with HIV-Associated Thrombotic 
Thrombocytopenic Purpura. J AIDS Clin Res 5: 311. doi:10.4172/2155-
6113.1000311
